Cannabinoid treatment for autism: a proof-of-concept randomized trial

Key Findings:  An oral form of a whole-plant cannabis-based extract containing CBD:THC in a ratio of 20:1 was given to pediatric patients diagnosed with autism spectrum disorder (ASD) dealing with disruptive behaviors. Compared to the placebo group the extract was associated with a significant drop in disruptive behavior (49%). Furthermore, the treatment was well tolerated. The oral administration of plant-derived cannabis extracts is well-tolerated and reduces disruptive behaviors in children with autism spectrum disorder (ASD), according to clinical trial data published in the journal Molecular Autism.

Type of Study:  Double Blind Human Trial

Study Sample Size:  150

Study Result:  Positive

Study Location(s):  Israel, United States

Year of Pub:  2021

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC)

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype III

Sub-Ratio: 20:1 (CBD:THC)

Route of Administration:  Oral (Ingestion)

Link to study